Our goal in the present study was to evaluate antitumor effects and frequency of tumor-infiltrating immune cells upon intratumoral injection of RGD fiber-mutant adenoviral vector (AdRGD) encoding the chemokines CCL17, CCL19, CCL20, CCL21, CCL22, CCL27, XCL1, and CX3CL1. Among eight kinds of chemokine-expressing AdRGDs, AdRGD-CCL19 injection most efficiently induced infiltration of T cells into established B16BL6 tumor parenchyma, whereas most of these T cells were perforin-negative in immunohistochemical analysis. Additionally, the growth of AdRGD-CCL19-injected tumors decreased only slightly as well as that of other tumors treated with each chemokine-expressing AdRGD, which indicated that accumulation of naive T cells in tumor tissue does not effectively damage the tumor cells. Tumor-bearing mice, in which B16BL6-specific T cells were elicited by dendritic cellbased immunization, demonstrated that intratumoral injection of AdRGD-CCL17, -CCL22, or -CCL27 could considerably suppress tumor growth and attract activated T cells. On the other hand, AdRGD-CCL19-injection in the immunized mice showed slight increase of tumor-infiltrating T cells compared to treatment using control vector. Collectively, although AdRGD-mediated chemokine gene transduction into established tumors would be very useful for augmentation of tumor-infiltrating immune cells, a combinational treatment that can systemically induce tumor-specific effector T cells is necessary for satisfactory antitumor efficacy.
Introduction
Tumor cells that generally accumulate mutations in the genome express molecules different qualitatively and quantitatively from normal cells. An immunosurveillance system for these molecules, known as the tumorassociated antigen (TAA), plays an important role in the elimination of cancer cells during the initial stage. [1] [2] [3] However, because tumor cells are inherently autologous cells and their immunogenicity is very weak as compared with pathogens (non-self) invading from the outside world, malignant tumor cells can evade immunosurveillance and then infringe upon various biological functions by uncontrollable proliferation and metastasis. In addition, several soluble factors secreted from tumor cells are known to induce failure in the host's immune function. 4, 5 Therefore, amelioration of illness exhibiting a growing tumor mass is difficult by innate immunity alone. Development of immunotherapy for cancer would involve the establishment of a methodology capable of enhancing recognition of tumor cell characteristics (differences from normal cells) by a patient's immune system, and accumulating activated immune effector cells at a local tumor site.
Cancer immunotherapy research has steadily progressed towards clinical application through cooperative fundamental research and clinical studies that have focused on adoptive transfer of lymphokine-activated killer cells or tumor-specific cytotoxic T lymphocytes (CTLs) 6, 7 and administration of TAA-component vaccine, 8 TAA-coding DNA vaccine, 9 genetically modified tumor cell-based vaccine, 10, 11 or TAA-delivered dendritic cell (DC)-based vaccine. [12] [13] [14] Although these approaches can induce and amplify tumor immunity in patients, satisfactory efficacy, including marked tumor regression or complete response, has not been previously reported in a clinical setting. One potential cause of these disappointing results is insufficient investigation and understanding of methods that improve accumulation of immune effector cells in tumor tissue. The principal objective of most conventional studies of cancer immunotherapy has been efficient induction and activation of effector cells. Therefore, even if effector cells that exhibited the ability to kill tumor cells were adequately induced in a patient, the efficacy of cancer immunotherapy would be considerably limited if effector cells were unable to infiltrate tumor tissue and come in contact with tumor cells. Innovative approaches capable of better controlling biodistribution of immune effector cells are needed to overcome the limitations of current therapy.
Chemokine-chemokine receptor coupling controls leukocytic migration and infiltration of local sites through cooperation with various cell adhesion molecules. 15 Chemokines, which are small (8-14 kDa) secreted basic proteins, comprise a superfamily that contains four subgroups: C chemokine, CC chemokine, CXC chemokine, and CX3C chemokine. 16 These subgroups are defined by the position of conservative cysteine residues in the Nterminal and interactions with their specific receptors, which belong to the superfamily of seven-transmembrane domain G-protein-coupled receptors. 17, 18 Initially, chemokines were identified as a group of cytokines capable of enhancing migration of neutrophils and monocytes, and functional analysis has focused on their role in inflammation. In the late 1990s, the sequence of immune chemokine, which primarily affects lymphocytes and DCs, was identified by a bioinformatics technique that used an EST database search. To date, more than 50 chemokines have been identified. Chemokines are now considered important molecules for cancer immunotherapy, which is based on the eradication of tumor cells as a consequence of interaction with immune cells that have migrated and accumulated in tumor tissues. [19] [20] [21] [22] [23] [24] We previously demonstrated that tumor cells transduced with RGD fiber-mutant adenoviral vector (AdRGD) encoding a chemokine gene could adequately secrete a biologically active chemokine, and that in vitro transfection established several chemokines as promising candidates for cancer treatment in three murine tumor models. 25, 26 Although the inoculation of chemokine-transduced tumor cells was very useful for screening antitumor effects through the promotion of chemokine secretion in tumor tissue, direct in vivo injection of chemokine-expressing vector into tumor tissue is required for the development of effective chemokine-based cancer immunogenetherapy. Thus, in the present study, we attempted to investigate tumor suppressive effects of intratumoral injection of AdRGD encoding murine chemokines CCL17, CCL19, CCL20, CCL21, CCL22, CCL27, XCL1, and CX3CL1, and identify immune cells capable of infiltrating tumor tissue in the murine B16BL6 melanoma model.
Materials and methods
Cell lines and mice HEK293 cells, the helper cell line for AdRGD propagation, were purchased from ATCC (Manassas, VA) and cultured in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum (FBS) and antibiotics. Murine melanoma B16BL6 cells (H-2   b   ) were obtained from JCRB cell bank (Tokyo, Japan) and grown in minimum essential medium supplemented with 7.5% FBS and antibiotics. EL4 cells, a T-lymphoma cell line of C57BL/6 origin, and YAC-1 cells, a lymphoma cell line highly sensitive to natural killer (NK) cells, were purchased from ATCC and maintained in RPMI 1640 medium supplemented with 10% FBS, 50 mM 2-mercaptoethanol, and antibiotics. Female C57BL/6 mice (H-2 b ), age 7-8 weeks, were purchased from Japan SLC Inc. (Hamamatsu, Japan), and were held under specific pathogen-free conditions. Animal experimental procedures were in accordance with the Osaka University guidelines for the welfare of animals in experimental neoplasia.
Vectors
Replication-deficient AdRGD was based on the adenovirus serotype 5 backbone with deletions of E1 and E3 regions. The RGD sequence for av-integrin-targeting was inserted into the HI loop of the fiber knob using a twostep method as previously described. 27 Eight murine chemokine-expressing AdRGDs (AdRGD-CCL17,  -CCL19, -CCL20, -CCL21, -CCL22, -CCL27, -XCL1,  and -CX3CL1) , 25, 26 gp100-expressing AdRGD (AdRGDgp100), 28 and luciferase-expressing AdRGD (AdRGDLuc) 27 were previously constructed by an improved in vitro ligation method. 27, 29, 30 All recombinant AdRGDs were propagated in HEK293 cells, purified by two rounds of cesium chloride gradient ultracentrifugation, dialyzed, and stored at À801C. Titers of infective AdRGD particles (plaque-forming unit; PFU) were evaluated by the end point dilution method using HEK293 cells.
Generation and viral transduction of DCs
DCs were prepared according to the method of Lutz et al. 31 with slight modification. Briefly, bone marrow cells flushed from the femurs and tibias of C57BL/6 mice were seeded at 0.5-1 Â 10 7 cells per sterile 100-mm bacterial grade culture dish in 10 ml of RPMI 1640 containing 10% FBS, 40 ng/ml recombinant murine granulocyte/macrophage colony-stimulating factor (kindly provided by KIRIN Brewery Co., Ltd, Tokyo, Japan), 50 mM 2-mercaptoethanol, and antibiotics. On day 3, another 10 ml of culture medium was added to the dish for medium replenishment. On day 6, 10 ml of the culture supernatant was collected and centrifuged at 1500 r.p.m. for 5 min at room temperature, and the pellet was resuspended in 10 ml of fresh culture medium, and then returned to the original dish to conserve unattached cells. On day 8, nonadherent cells were harvested and used as DCs. In transduction using AdRGD-gp100, DCs were suspended at a concentration of 5 Â 10 6 cells/ml in FBSfree RPMI 1640 and placed in a 50-ml conical tube. AdRGD-gp100 was added at 25 PFU/cell, the suspension was mixed well, and the tube was incubated at 371C for 2 h with occasional gentle agitation. The cells were washed three times and resuspended with phosphate-buffered saline (PBS), and used in subsequent experiments as gp100/DCs.
Protocol for intratumoral injection of chemokineexpressing AdRGD (Protocol-1) C57BL/6 mice were intradermally inoculated with 4 Â 10 5 B16BL6 cells in the right flank. After 6 days, established tumors with diameters of 5-7 mm were injected with each vector at 3 Â 10 8 PFU in 50-ml PBS.
Protocol for intratumoral injection of chemokineexpressing AdRGD in combination with gp100/DC immunization (Protocol-2) B16BL6 cells were intradermally inoculated into C57BL/6 mice in the right flank at 4 Â 10 5 cells/mouse. The next day, the mice were intradermally injected with 10 6 gp100/ DCs in the left flank. Then, the 5-7 mm in diameter tumors were injected with each vector at 3 Â 10 8 PFU in 50-ml PBS.
Evaluation of tumor growth
The major and minor axes of the tumors treated with Protocol-1 or -2 were measured using microcalipers, and tumor volume was calculated by the following formula: (tumor volume; mm 3 ) ¼ (major axis; mm) Â (minor axis; mm) 2 Â 0.5236. The mice were euthanized when one of the two measurements was greater than 20 mm.
Histopathological and immunohistochemical examination of tumor sections
Tumor-bearing mice were killed 2 days after the intratumoral injection of chemokine-expressing AdRGD in Protocol-1 or -2. For histopathological examination, the tumor nodules were harvested, placed in neutral 10% formalin/PBS, and embedded in paraffin. Sections (5 mm in thickness) were prepared for hematoxylin and eosin (HE) staining. For immunohistochemical analysis, the fresh tumor nodules were embedded in OCT compound (Sakura Finetechnical Co., Ltd, Tokyo, Japan), and frozen in liquid nitrogen. Frozen sections (5 mm in thickness) were fixed in 4% paraformaldehyde, washed with PBS, and then stored at À801C until following immunostaining procedures. Only in the sections for Ki-67 detection, antigen retrieval treatment was performed with target retrieval solution pH6 (DakoCytomation Co., Ltd, Kyoto, Japan) at 951C for 10 min. The immunostaining procedures, which included blocking for endogenous peroxidase activity with peroxidase blocking solution (DakoCytomation), blocking for nonspecific binding of the subsequently used immunoreagents with 5% bovine serum albumin, incubation with optimal dilution of antibody, incubation of reagent(s) for detection, and development with 3,3 0 -diaminobenzidine, were carried out on automated immunostaining system (Autostainer Plus, DakoCytomation). Between all incubation steps, the tumor sections were washed with Tris-bufferd saline containing Tween-20. The following antibodies were used as primary antibody; rat anti-mouse Ki-67 monoclonal antibody (mAb) (TEC-3; DakoCytomation), rat anti-mouse CD34 mAb (RAM34; BD Biosciences, San Jose, CA), rat anti-mouse F4/80 mAb (C1:A3-1; Serotec Co., Ltd, Sapporo, Japan), rabbit anti-human CD3 polyclonal antibody (DakoCytomation), rabbit antiasialoGM1 polyclonal antibody (Wako Pure Chemical Industries, Ltd, Osaka, Japan), rat anti-mouse CD4 mAb (RM4-5; BD Biosciences), rat anti-mouse CD8 mAb (KT15; Serotec Co., Ltd), rat anti-mouse perforin mAb (P1-8; DakoCytomation), or hamster anti-mouse CD11c mAb (N418; CHEMICON International, Inc., Temecula, CA). Rat anti-mouse Ki-67 mAb was detected with biotinylated anti-rat Ig (DakoCytomation) and horseradish peroxidase (HRP)-conjugated streptavidin (DakoCytomation). Rabbit anti-human CD3 polyclonal antibody and rabbit anti-asialoGM1 polyclonal antibody were detected with ENVISION þ Rabbit/HRP (DakoCytomation). Hamster anti-mouse CD11c mAb was detected with HRP-conjugated anti-hamster Ig (BD Biosciences) and CSA II System (DakoCytomation). Other primary antibodies were detected with HRPconjugated anti-rat Ig (Santa Cruz Biotechnology, Inc., Santa Cruz, CA) and CSA II System. The sections were finally counterstained with hematoxylin. The number of immunostained cells in six fields per specimen was counted under a light microscope using Â 400 magnification.
Europium-release assay for cytolytic activity of CTLs B16BL6 cells were intradermally inoculated into C57BL6 mice in the right flank at 4 Â 10 5 cells/mouse. The next day, the mice were intradermally injected with 10 6 gp100/ DCs or PBS in the left flank. At 1 week after immunization, nonadherent splenocytes were prepared from these tumor-bearing mice and restimulated in vitro using B16BL6 cells, which were cultured in media containing 100 U/ml recombinant murine interferon (IFN)-g (PeproTech EC Ltd, London, UK) for 24 h and inactivated with 50 mg/ml mitomycin C at 371C for 30 min, at an effector:stimulator ratio of 10:1 in RPMI 1640 supplemented with 10% FBS, 50 mM 2-mercaptoethanol, and antibiotics. After 5 days, the splenocytes were collected and used as effector cells. Target cells (IFN-g-stimulated B16BL6, IFN-g-stimulated EL4, and YAC-1 cell) were europium-labeled and a europiumrelease assay was performed as previously described. 32 Cytolytic activity was determined using the following formula: (% of lysis) ¼ ((experimental europium-releaseÀspontaneous europium-release)/(maximum europiumreleaseÀspontaneous europium-release)) Â 100. Spontaneous europium-release of the target cells was o15% of maximum europium-release by detergent.
Reverse transcription-polymerase chain reaction (RT-PCR) analysis of activation status of tumor-infiltrating immune cells Tumors were collected 2 days after intratumoral injection in Protocol-1 and -2, and total RNA was isolated using Sepasol-RNA I Super (Nacalai Tesque, Inc., Kyoto, Japan), according to the manufacturer's instructions. RT proceeded for 60 min at 421C in a 50 ml reaction mixture containing 5 mg total RNA treated with DNase I, 10 ml 5 Â RT buffer, 5 mM MgCl 2 , 1 mM dNTP mix, 1 mM random primer (9-mer), 1 mM oligo(dT) 20 , and 100 U ReverTra Ace (TOYOBO Co., Ltd, Osaka, Japan). PCR amplification of the perforin, granzyme B, IFN-g, and b-actin transcripts was performed in 50 ml of a reaction mixture containing 1 ml of RT material, 5 ml 10 Â PCR buffer, 1.25 U Taq DNA polymerase (TOYOBO Co., Ltd), 1.5 mM MgCl 2 , 0.2 mM dNTP, and 0.4 mM primers. The sequences of the specific primers were as follows: murine perforin: forward, 5 0 -ttt cgc ctg gta caa aaa cc-3 0 ; reverse, 5 0 -cag tcc tgg ttg gtg acc tt-3 0 ; murine granzyme B: forward, 5 0 -ctc gac cct aca tgg cct ta-3 0 ; reverse, 5 0 -gaa agg aag cac gtt tgg tc-3 0 ; murine IFN-g: forward, 5 0 -gct ttg cag ctc ttc ctc at-3 0 ; reverse, 5 0 -tga gct cat tga atg ctt gg-3 0 ; murine b-actin: forward, 5 0 -tgt gat ggt ggg aat ggg tca g-3 0 ; reverse, 5 0 -ttt gat gtc acg cac gat ttc c-3 0 . After denaturation for 2 min at 951C, 20 cycles of denaturation for 30 s at 951C, annealing for 30 s at 601C (for perforin and b-actin) or 621C (for granzyme B and IFN-g), and extension for 30 s at 721C were repeated and followed by completion for 4 min at 721C. The PCR product was electrophoresed through a 3% agarose gel, stained with ethidium bromide, and visualized under ultraviolet radiation. EZ Load (Bio-Rad Laboratories, Inc., Tokyo, Japan) was used as a 100 bp molecular ruler. The expected PCR product sizes were 680 bp (perforin), 507 bp (granzyme B), 379 bp (IFN-g), and 514 bp (b-actin).
Results

Growth and histology of B16BL6 tumor injected with chemokine-expressing AdRGD
In order to evaluate the suppressive effect of in vivo chemokine-gene transduction against established tumor, we investigated the changes in tumor volume after intratumoral injection of each chemokine-expressing AdRGD in murine B16BL6 melanoma model (Figure 1) . Growth of B16BL6 tumor injected with AdRGD-Luc (control vector) at 3 Â 10 8 PFU was equal to that of vehicle-injected tumor. On the other hand, mice injected intratumorally with each chemokine-expressing AdRGD exhibited slight delay of tumor growth as compared with control groups, and the rank order of the suppressive effect in eight chemokine-treated groups was CCL19
Next, histological changes of tumors injected with chemokine-expressing AdRGD were examined by HE staining (Figure 2a On day 2 after intratumoral injection, differences in frequency of granulocytic infiltration, size of necrotic area with undernourishment, proliferative state of tumor cells, and frequency of neovascularity were not observed among tumors injected with PBS, AdRGDLuc, AdRGD-CCL17, and AdRGD-CCL19. Similar pathological findings were also observed in other tumors treated with AdRGD-CCL20, -CCL21, -CCL22, -CCL27, -XCL1, or -CX3CL1 (data not shown). These observations revealed that AdRGD particle itself or the expressed chemokines did not contribute directly to injury of tumor cells and did not facilitate formation/breakdown of tumor vessels. Therefore, the data suggested that a delay in growth of B16BL6 tumor in response to direct injection of chemokine-expressing AdRGD might be caused by promotion of immune cell infiltration into tumor tissue by the secreted chemokines. -h and 4a ). In addition, subset analysis of the T cells that infiltrated the AdRGD-CCL19-injected tumor revealed that CCL19 induced significant infiltration of both CD4 þ and CD8 þ subsets, composed of helper T cells (Th) and CTLs, respectively, into tumor tissue (Figures 3m, n and 4a) . However, most of these T cells attracted by CCL19 were not in a sensitized/activated state as demonstrated by the low amounts of perforinpositive cells in tumors injected with AdRGD-CCL19 (Figures 3o and 4a) . Similarly, the perforin-positive cells were hardly recognized in tumors of several chemokine groups, which showed moderate increase of tumorinfiltrating CD4 þ and CD8 þ subsets (Figure 4a ), indicating that intratumoral injection using our eight chemokine-expressing AdRGDs did not significantly attract activated effector cells that possessed potent killing activity against tumor cells. Considerable enhancement of NK cell-infiltration into parenchyma of tumor tissue was not observed in any groups injected with chemokine-expressing AdRGD (Figures 3i-l and 4a) . On the other hand, intratumoral injection of AdRGD-CCL17 resulted in marked difference in the number of NK cells in the peritumoral portion as compared with the Chemokine-based cancer immunogenetherapy N Okada et al AdRGD-Luc-injected group, and moderate enhancement of NK cell-accumulation was observed at periphery of tumors injected with AdRGD-CCL19, -CCL21, or -CCL22 (Figures 3i-l and 4b) . Immunostaining against CD11c showed that intratumoral injection of each chemokine-expressing AdRGD could not induce significant accumulation of DCs, which are the most potent antigen-presenting cells (Figure 4a) .
Taken together, these data demonstrate that intratumoral injection of AdRGD-CCL19 drastically promotes T-cell infiltration into B16BL6 tumor tissue, and AdRGD-CCL17 injection most efficiently induces NK cell-accumulation at the peritumoral area, but not inside the tumor tissue. Moreover, perforin-positive immune cells were detected at extremely low levels in all tumors, suggesting that the tumor-infiltrating naive T cells attracted by chemokine gene transduction should be activated in tumor-specific manner in order to achieve more effective tumor elimination.
Anti-B16BL6 tumor efficacy of combinational therapy using gp100/DC-immunization and intratumoral injection of chemokine-expressing AdRGD We theorized that combination therapy, which includes a treatment that can activate tumor-specific immune response in the host, might be required for more effective application of chemokine-expressing AdRGD to cancer immunotherapy. We previously demonstrated that vaccination with DCs transduced with gp100, a melanomaassociated antigen, by using AdRGD could induce potent protective effects against murine B16BL6 melanoma challenge based on enhancement of gp100-specific CTL , k) , or AdRGD-CCL19 (d, h, l, m, n, o) at 3 Â 10 8 PFU. Likewise, PBS was administered into control tumors (a, e, i). On day 2 after intratumoral injection, immunohistochemical staining against F4/80 (to detect macrophages; a-d), CD3 (for identification of T cells; e-h), and asialoGM1 (for identification of NK cells; i-l) was performed using frozen tumor sections. For determining the subset and the activation status of T cells in AdRGD-CCL19-injected tumor, immunohistochemical staining against CD4 (m), CD8 (n), and perforin (o) was performed using serial sections for h. Original magnifications are Â 200.
Chemokine-based cancer immunogenetherapy N Okada et al activity. 33 Thus, antitumor efficacy of a treatment combining intradermal immunization of gp100/DCs and intratumoral injection of chemokine-expressing AdRGD was investigated in B16BL6 tumor-bearing mice, according to the Protocol-2 described in the Materials and methods section.
In order to confirm the activation of systemic immunity in tumor-bearing mice immunized with gp100/DCs, we first evaluated CTL activity in splenocytes from these mice. Single immunization with gp100/DCs at a site distant from the tumor-inoculation site could promote killing activity of effector cells targeting B16BL6 cells (Figure 5a ). As H-2 haplotype-matched irrelevant EL4 cells and YAC-1 cells, which are highly susceptible to NK activities, were not injured by these effector cells ( Figure  5b and c) , gp100/DC-administration could sensitize and activate gp100-specific CTLs in B16BL6 tumor-bearing mice as well as intact mice. As shown in Figure 6 , mice 8 PFU. Likewise, PBS was administered into control tumors. On day 2 after intratumoral injection, immunohistochemical staining against CD3, CD4, CD8, asialoGM1, perforin, and CD11c was performed using frozen tumor sections. Then, the number of positive cells in intratumoral (a) or peritumoral (b) sections was assessed by counting six fields per specimen under Â 400-magnification . The data represent the mean7s.e. of results from three tumors. Statistical analysis was carried out by Welch's t-test: *Po0.01, **Po0.001 versus AdRGD-Luc-injected group.
Chemokine-based cancer immunogenetherapy N Okada et al injected intratumorally with PBS after gp100/DC-immunization did not exhibit considerable suppression of B16BL6 tumor growth as compared with unimmunized group, indicating that regression of B16BL6 tumor that had begun to proliferate was very difficult with only a single dose of gp100/DCs. At initial stage until day 11 after intratumoral injection, tumor growth in mice treated with AdRGD-Luc after gp100/DC-immunization was obviously delayed as compared with that in the PBSinjected group. We speculated that this suppressive effect was based on the activity of immune cells, including activated CTLs, which were attracted to tumor tissue by an inflammatory response to AdRGD-administration. In comparison with the control groups, AdRGD-CCL19 injection, which induced massive tumor-infiltrating T cells in unimmunized mice, only slightly delayed tumor growth in gp100/DC-immunized mice, although the effect was better than that by injection of AdRGD-CCL20 or -CCL21. Intratumoral injection of AdRGD-XCL1 or -CX3CL1 was not effective for promoting the tumor suppressive effect based on gp100/DC-immunization. On the other hand, intratumoral injection of AdRGD-CCL17, -CCL22, or -CCL27 in combination with gp100/DC-immunization could remarkably improve antitumor efficacy.
Accumulation and activation state of immune cells in tumor treated with the combination of gp100/DCimmunization and chemokine-expressing AdRGD injection B16BL6 tumors were harvested 2 days after intratumoral injection of chemokine-expressing AdRGD (Protocol-2) and were analyzed for the levels of infiltrating T cells by immunohistochemical staining. As shown in Figure 7 , tumors injected with AdRGD-CCL17, -CCL22, or -CCL27 exhibited enhanced CD3 þ T-cell accumulation, Figure 5 Enhanced tumor-specific CTL activity in B16BL6 tumorbearing mice by gp100/DC-immunization. B16BL6 cells were intradermally inoculated into the right flank of C57BL/6 mice at 4 Â 10 5 cells/mouse. One day later, the mice were intradermally injected with 10 6 gp100/DCs (K) or PBS (J) in the left flank. At 1 week after immunization, nonadherent splenocytes were prepared from these mice, and then were restimulated in vitro for 5 days with IFN-g-stimulated and mitomycin C-inactivated B16BL6 cells. A cytolytic assay using the restimulated splenocytes was performed against IFN-g-stimulated B16BL6 (a), IFN-g-stimulated EL4 (b), and YAC-1 (c) cells. The data represent the mean7s.e. of three independent cultures from three individual mice. Chemokine-based cancer immunogenetherapy N Okada et al whereas the number of T cells in tumor tissue was only slightly elevated by injection of AdRGD-CCL19, -CCL20, or -CCL21, and did not change between the AdRGD-XCL1-or AdRGD-CX3CL1-injected group and the AdRGD-Luc-injected group. These data disagreed with the observation that intratumoral injection of AdRGD-CCL19 could attract a large number of T cells in mice without gp100/DC-immunization as shown in Figures 3h and 4a , suggesting that responsiveness of T cells for chemokines was altered by the activation state of the host's immune system, that is, sensitization of T cells by gp100/DC-administration. Importantly, the levels of tumor-infiltrating T cells showed positive correlation for antitumor efficacy ( Figure 6 ) in mice treated with gp100/ DC immunization and each chemokine-expressing AdRGD injection. Because the number of infiltrating NK cells and DCs was low in tumors injected with any AdRGD in this combinational protocol as well as in Protocol-1 (data not shown), we theorized that infiltrating CTLs were the major effector cells responsible for improved anti-B16BL6 tumor effects. In order to evaluate the activation state of tumorassociated CTLs, we performed RT-PCR analysis specific for perforin, granzyme B, and IFN-g, which are the major cytotoxic molecules and secreted cytokines in activated CTLs (Figure 8 ). We focused on tumors treated with AdRGD-CCL17 and AdRGD-CCL19, which induced the most effective T-cell infiltration in Protocol-2 and -1, respectively. The combination with gp100/DC-immunization notwithstanding, PCR products derived from transcripts of perforin, granzyme B, or IFN-g were detected at higher levels in tumors injected with AdRGD-CCL17 or AdRGD-CCL19 as compared with AdRGD-Luc-injected tumors. In the absence of gp100/DC immunization, AdRGD-CCL19-injected tumors expressed more perforin-and granzyme B-specific mRNA than AdRGD-CCL17-injected tumors, whereas intratumoral injection of AdRGD-CCL17 in combination with gp100/DC immunization induced higher perforin, granzyme B, and IFN-g mRNA expression in tumor tissue than AdRGD-CCL19 injection. In addition, expression levels of perforin, granzyme B, and IFN-g mRNA were increased in AdRGD-CCL17-injected groups by receiving gp100/ DC immunization. On the other hand, gp100/DC immunization of AdRGD-CCL19-injected groups tended to decrease or did not alter mRNA expression levels of these three activation markers. Though intratumoral injection with AdRGD-CCL19 in protocol-1 was able to induce T-cell infiltration much more efficiently than AdRGD-CCL17 injection in protocol-2 (Figures 4a and  7c) , RT-PCR analysis revealed that AdRGD-CCL17-injected tumor in gp100/DC-immunized mice contained 6 gp100/DCs in the left flank. The tumor (5-7 mm in diameter) in Protocol-1 or -2 was injected with AdRGD-CCL17, AdRGD-CCL19, or AdRGD-Luc at 3 Â 10 8 PFU. Likewise, PBS was administered into control tumors. After 2 days, total RNA was isolated from the tumors collected from these mice, and then RT-PCR, specific for perforin, granzyme B, and IFN-g transcripts, was performed as described in the Materials and methods section. The PCR products were electrophoresed through a 3% agarose gel, stained with ethidium bromide, and visualized under ultraviolet light.
Chemokine-based cancer immunogenetherapy N Okada et al activated T cells in higher frequency as compared with tumor treated with AdRGD-CCL19 injection alone. These results correlate closely with differences in the antitumor effects (Figures 1 and 6 ), strongly suggesting that efficient accumulation of activated tumor-specific CTLs at a local tumor site is a key factor for establishment of efficacious cancer immunotherapy.
Discussion
Investigations of the relationship between the prognosis and the infiltration frequency of tumor-associated immune cells in patients with cancer have indicated that post-treatment recurrence or metastasis is significantly suppressed in cases that exhibit high immune cellinfiltration in primary tumor tissue, [34] [35] [36] and it is widely believed that T cells represent the most potent antitumor effector cells. [37] [38] [39] Therefore, the establishment of immunotherapy capable of promoting tumor cell-immune cell interaction is considered critical for improving the cure rate for cancer. Based on these results, an approach that attempts to reinforce immune cell accumulation in tumor tissue by applying chemokines, which control migration and infiltration of immune cells into the local site, is very attractive for the development of efficacious cancer immunotherapy. We previously demonstrated that tumor cells transduced with AdRGD encoding chemokine genes could produce and secrete chemokines that exhibit original bioactivity, and that inoculation with chemokine gene-transfected tumor cells was very useful for screening antitumor effects based on facilitation of chemokine secretion in tumor tissue. 25, 26 In the present study, in order to evaluate the potential of chemokine-based immunogenetherapy for cancer by using an AdRGD system capable of efficient gene transduction in various tumors, we examined antitumor efficacy and accumulation of tumor-associated immune cells in mice directly injected with chemokine-expressing AdRGD into established tumor tissue.
An established murine B16BL6 melanoma injected with AdRGD-CCL17, -CCL19, -CCL20, -CCL21, -CCL22, -CCL27, -XCL1, or -CX3CL1 exhibited slightly delayed growth compared with control vector-injected tumor. Moreover, immunohistochemical analysis of these tumors demonstrated that intratumoral injection of AdRGD-CCL19 could significantly induce both CD4 þ and CD8 þ T-cell infiltration in parenchyma of tumor tissue, and that AdRGD-CCL17 injection was superior in promoting NK cell accumulation at the peritumoral site. Generally, the infiltration of immune cells rarely occurs in newly formed vessels in solid tumor, and immune cells that penetrate from existing blood vessels, which are present around tumor tissue, arrive at and accumulate in tumor parenchyma through the tumor border region. 40 This explains our observation that NK cells accumulated in the tumor peripheral zone, but did not infiltrate the tumor parenchyma upon intratumoral injection of chemokineexpressing AdRGD. On the other hand, we speculated that T-cell infiltration occurred directly from tumor vessels in the AdRGD-CCL19-treated group, because a large number of T cells were observed in the center of tumor tissue as well as near the border. This theory is supported by a previous report that CCL19 could increase the expression of cell adhesion molecules on vascular endothelial cells. 41 Although CCL19 and CCL21 are ligand for an identical chemokine receptor (CCR7), the level of T-cell infiltration in AdRGD-CCL21-injected tumors was obviously lower than that in AdRGD-CCL19-injected tumors. Similarly, regarding CCL17 and CCL22, which shared CCR4 as their receptor, the number of NK cells at periphery of AdRGD-CCL22-injected tumors was half of that of AdRGD-CCL17-injected tumors. Because chemokines are heparin/heparan sulfate-binding proteins and this property modulates their activity, diffusion, and stability in tissue, we speculated that an affinity to heparin/heparan sulfate of each chemokine might determine the difference of immune cell infiltration between CCL19-and CCL21-transduced tumors or between CCL17-and CCL22-transduced tumors. Previous studies have shown that intratumoral injections of CCL20 and CCL21 induce a large accumulation of mature DCs related with strong antitumor responses. 20, 42 However, we did not detect significant increase of infiltrating CD11c þ DCs in B16BL6 tumors injected with any chemokine-expressing AdRGDs including AdRGD-CCL20 and -CCL21. We speculated that the disagreement between our observation and the results in previous studies was caused by a difference of the tumor model which was examined. Therefore, in order to select appropriate chemokine for intratumoral gene transduction to augment tumor-infiltrating immune cells efficiently, we need to consider not only its receptorspecificity but also its in vivo characteristics and variety of tumors. However, we could not recognize a correlation between tumor suppressive effect and the number of tumor-infiltrating immune cells in mice treated with each chemokine-expressing AdRGD. Because most immune cells that infiltrated into tumors with injection of chemokine-expressing AdRGD were perforin-negative, that is, in naive status, combinational therapy that included another treatment, which could prime and activate immune effector cells, would be required for achievement of more potent antitumor efficacy.
We previously succeeded in efficiently transducing genes into DCs by applying the AdRGD system rather than a conventional vector, 28, 43 and demonstrated that DCs transduced with the TAA gene using AdRGD are effective vaccine carriers that induce tumor-specific immune responses in mice. 33, 44 Thus, we evaluated the antitumor effect in mice of intratumoral injection of chemokine-expressing AdRGD combined with intradermal immunization of DCs transduced with gp100 by AdRGD. Lytic activity of B16BL6-specific CTLs in splenocytes from B16BL6 tumor-bearing mice was considerably enhanced by single gp100/DC-immunization, indicating that administration of TAA/DCs could promote initiation and amplification of tumor immunity in individuals that exhibited ongoing tumor growth (ther-apeutic protocol) as well as in intact mice (vaccine protocol). In combination with gp100/DC-immunization, intratumoral injection with AdRGD-CCL17, -CCL22, or -CCL27 markedly suppressed B16BL6 tumor growth in mice. In addition, immunohistochemical analysis and RT-PCR analysis using RNA isolated from treated tumors revealed that CCL17-, CCL22-, or CCL27-gene transduction induced efficient accumulation of activated T cells in tumor tissue. CCL19, on the other hand, only slightly induced activated T-cell accumulation in tumors of gp100/DC-immunized mice, whereas naive T cells were dramatically attracted to tumors injected with AdRGD-CCL19 alone. These conflicting results can be explained by the evidence that CCR7, which is the corresponding receptor for CCL19, is expressed on naive T cells, but not on effector-type T cells. 45 Kim et al. demonstrated that DC-stimulation led naive T cells to downregulation of lymphoid tissue homing related CCR7 and CXCR5, and upregulation of Th1/2 effector tissue-targeting chemoattractant receptors such as CCR4 (receptor for CCL17 and CCL22), CCR5, CXCR6, and CRTH2. 46 In addition, Mullins et al. reported that coexpression of CCR4 and CXCR3 by activated CD8 þ T cells derived from the peripheral blood or tumor-involved lymph nodes of patients with stage III metastatic melanoma was significantly associated with enhanced survival.
47 CCR10 (receptor for CCL27) is known as a chemokine receptor that is preferentially expressed among blood leukocytes by a subset of memory CD4 þ and CD8 þ T cells, and CCR10-positive T cells that coexpress the skin-homing receptor, cutaneous lymphocyte antigen, can act as both 'central' and 'effector' memory T cells. 48 These previous results supported our data that intratumoral injection of AdRGD-CCL17, -CCL22, or -CCL27, but not AdRGD-CCL19, was effective for promoting the anti-B16BL6 tumor efficacy and the infiltration of immune effector cells in mice immunized with gp100/DCs. Therefore, the selection of chemokine in cancer immunogenetherapy must consider the host's immune activation status and characteristics of other combined therapies on immunomodulation.
In conclusion, our results revealed that chemokine gene transduction into established tumors using AdRGD could enhance accumulation of immune cells, and would greatly contribute to the development of efficacious cancer immunogenetherapy based on 'Immune Cell Delivery System'. Additionally, combinational therapy that included immunization with TAA-delivered DCs and intratumoral injection of chemokine-expressing AdRGD, such as AdRGD-CCL17, -CCL22, and -CCL27, could more effectively suppress tumor growth as compared with each treatment alone, indicating that the combined treatment, which can systemically induce tumor-specific effector T cells, is a promising strategy for potentiating antitumor efficacy and tumor-infiltrating effector cells by direct injection of chemokine-expressing vector into tumors. Now, in order to apply our chemokine genebased cancer immunotherapy to not only primary tumors but also metastatic tumors in which intratumoral injection of vectors is physically difficult, we are pushing forward development of transductionally and transcriptionally tumor-targeting vector, which can specifically deliver a chemokine gene into tumor cells by systemic administration. 49, 50 Abbreviations AdRGD, RGD fiber-mutant adenoviral vector; CTL, cytotoxic T lymphocyte; DC, dendritic cell; FBS, fetal bovine serum; HE, hematoxylin and eosin; IFN, interferon; mAb, monoclonal antibody; NK, natural killer; PBS, phosphate-buffered saline; PFU, plaque-forming unit; RT-PCR, reverse transcription-polymerase chain reaction; TAA, tumor-associated antigen; Th, helper T cell.
